Paysign Reports Q3 Earnings Beat Driven by Significant Pharma Revenue Growth
Paysign (PAYS) reported third-quarter financial results that exceeded analyst expectations for both earnings and revenue. The company posted a GAAP EPS of $0.11, beating estimates by $0.02, while total revenue reached $30.8 million, representing a 42.6% increase year-over-year and surpassing projections by $1.78 million. The primary driver for the growth was the pharmaceutical segment, which saw revenue surge by 109.8% to $16.62 million compared to the same period last year. This expansion is supported by the company's successful addition of 62 net patient affordability programs over the past 12 months.
